Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of S-1 in Combination with Sorafenib in Metastatic Renal Cell Carcinoma
jRCT2080220941Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and sorafenib in metastatic renal cell carcinoma (mRCC), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
tegafursorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on jRCT2080220941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220941.